136 results
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
for the Pompe community. I am just so immensely proud of our team, and so very grateful to everyone who has worked to bring this medicine … milestone for Amicus. We are grateful to the Pompe community, particularly the patients, caregivers, families, researchers, and physicians who have
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
26 Feb 19
Other Events
7:03am
an enormous amount of suffering. This is our mission at Amicus and we are honored to be a part of the exciting Philadelphia research community.”
Under … facility will be located at 3675 Market Street in uCity Square, a 6.5 million square-foot, mixed-use knowledge community consisting of office
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
2 Aug 21
Amicus Therapeutics Announces European Commission Approval of Galafold® (migalastat) for Adolescents with Fabry Disease
7:00am
for the Fabry community in the EU, as it gives those patients as young as 12 years of age with an amenable mutation a new treatment option for the first … time in more than 15 years. We are grateful to this wonderful and passionate community, particularly the patients, physicians, and families who have made
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
are seeking new treatments. We are grateful to the global Pompe community who have helped advance this therapy, especially the patients, families … the impact that this treatment is having for patients. Having widespread access to this treatment is an exciting development for the Pompe community
8-K
EX-99.1
FOLD
Amicus Therapeutics Inc
31 Aug 15
Amicus Therapeutics to Acquire
12:00am
and is transformative for the Epidermolysis Bullosa, or EB, community as well as the shareholders of Amicus and Scioderm,” said John F. Crowley … community that, together with Scioderm, understands our sense of urgency to see a treatment approved for EB,” said Brett Kopelan, Executive Director
8-K
EX-99.1
9e1f ze7xdqzytcc
23 Mar 20
Other Events
7:01am
8-K
EX-99.1
3gibrv2
10 Aug 18
Other Events
4:33pm
8-K
EX-99.1
sxe0sw36lb3 ei2g
29 May 19
Entry into a Material Definitive Agreement
6:32am
8-K
EX-99.1
sh0asxvjyzcz5o26k
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
EX-99.2
jjux38
31 Aug 15
Amicus Therapeutics to Acquire
12:00am
8-K
EX-99.1
cls1ac
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
EX-99.1
rp2qzcp 816tz
16 Dec 22
Amicus Therapeutics Receives Positive CHMP Opinion for Pombiliti™ (cipaglucosidase alfa) for Late-Onset Pompe Disease
8:17am
8-K
EX-99.2
xh8dg2c3 3j4n
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
EX-99.2
jav0gzhg43rdxx5eeim
30 Sep 15
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.1
hxgday2f
23 Jul 12
Entry into a Material Definitive Agreement
12:00am
8-K
EX-99.2
8rym7 k0dm
20 Aug 14
Regulation FD Disclosure
12:00am
8-K
EX-99.2
97shp8
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
EX-99.2
tgztl0g8snxbacd0u
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
CORRESP
pr5tgnim fp
30 Mar 09
Correspondence with SEC
12:00am
8-K
EX-99.2
rhplx25mxen2cnkz
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am